LONGITUDINAL ANALYSIS OF NEUROCOGNITIVE OUTCOMES IN PATIENTS WITH GLIOBLASTOMA (GBM) ENROLLED IN RTOG 0825

被引：0

作者：

Wefel, Jeffrey ^{[1
]}

Pugh, Stephanie ^{[2
]}

Armstrong, Terri ^{[1
]}

Gilbert, Mark ^{[1
]}

Won, Minhee ^{[2
]}

Wendland, Merideth ^{[3
]}

Brachman, David ^{[4
]}

Brown, Paul ^{[1
]}

Crocker, Ian ^{[5
]}

Robins, H. Ian ^{[6
]}

Lee, R. Jeffrey ^{[7
]}

Mehta, Minesh ^{[8
]}

机构：

[1] UT MD Anderson Canc Ctr, Houston, TX USA

[2] Radiat Therapy Oncol Grp, Philadelphia, PA USA

[3] US Oncol Willamette Valley Canc Inst, Eugene, OR USA

[4] Arizona Oncol Serv Fdn, Phoenix, AZ USA

[5] Emory Univ, Atlanta, GA 30322 USA

[6] Univ Wisconsin Hosp, Madison, WI USA

[7] Intermt Med Ctr, Murray, UT USA

[8] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

来源：

NEURO-ONCOLOGY | 2013年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：97 / 97

页数：1

共 50 条

[1] Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825
Wefel, Jeffrey Scott
Pugh, Stephanie L.
Armstrong, Terri S.
Gilbert, Mark R.
Won, Minhee
Wendland, Merideth M.
Brachman, David
Komaki, Ritsuko
Crocker, Ian R.
Robins, H. Ian
Lee, R. Jeffrey
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825
Armstrong, Terri S.
Won, Minhee
Wefel, Jeffrey Scott
Gilbert, Mark R.
Pugh, Stephanie L.
Brachman, David
Komaki, Ritsuko
Crocker, Ian R.
Robins, H. Ian
Lee, R. Jeffrey
Mehta, Minesh P.
Wendland, Merideth M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] COMPARATIVE IMPACT OF TUMOR AND TREATMENT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH GLIOBLASTOMA (GBM) ENROLLED IN RTOG 0825
Armstrong, Terri S.
Won, Minhee
Wefel, Jeffrey S.
Gilbert, Mark R.
Pugh, Stephanie
Wendland, Meredith M.
Brachman, David G.
Brown, Paul D.
Crocker, Ian R.
Robins, H. Ian
Lee, R. Jeffrey
Mehta, Minesh
NEURO-ONCOLOGY, 2013, 15 : 226 - 226
[4] Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825
Hall, W. A.
Pugh, S. L.
Gilbert, M. R.
Wefel, J. S.
Armstrong, T.
Wendland, M. M.
Brachman, D. G.
Roof, K. S.
Brown, P. D.
Crocker, I. R.
Robins, H. I.
Lee, R. J.
Chao, S. T.
Kim, L.
Srkalovic, G.
Fisch, B. M.
Mehta, M. P.
Curran, W. J., Jr.
Movsas, B.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S110 - S110
[5] Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
Wefel, Jeffrey S.
Armstrong, Terri S.
Pugh, Stephanie L.
Gilbert, Mark R.
Wendland, Merideth M.
Brachman, David G.
Roof, Kevin S.
Brown, Paul D.
Crocker, Ian R.
Robins, H. Ian
Hunter, Grant
Won, Minhee
Mehta, Minesh P.
NEURO-ONCOLOGY, 2021, 23 (07) : 1125 - 1138
[6] RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825
Zhou, Renke
Scheurer, Michael
Vera-Bolanos, Elizabeth
Gilbert, Mark
Bondy, Melissa
Sulman, Eric
Hilsenbeck, Sue
Wendland, Merideth
Brachman, David
Roof, Kevin
Komaki, Ritsuko
Deutsch, Melvin
Andrews, David
Anderson, Bethany
Lee, R. Jeffrey
Pugh, Stephanie
Armstrong, Terri
NEURO-ONCOLOGY, 2014, 16
[7] Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Sulman, Erik P.
Won, Minhee
Blumenthal, Deborah T.
Vogelbaum, Michael A.
Colman, Howard
Jenkins, Robert B.
Chakravarti, Arnab
Jeraj, Robert
Brown, Paul D.
Jaeckle, Kurt A.
Schiff, David
Dignam, James
Atkins, James Norman
Brachman, David
Werner-Wasik, Maria
Komaki, Ritsuko
Gilbert, Mark R.
Mehta, Minesh P.
Aldape, Kenneth D.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Sulman, Erik P.
Won, Minhee
Blumenthal, Deborah T.
Vogelbaum, Michael A.
Colman, Howard
Jenkins, Robert B.
Chakravarti, Arnab
Jeraj, Robert
Brown, Paul D.
Jaeckle, Kurt A.
Schiff, David
Dignam, James
Atkins, James Norman
Brachman, David
Werner-Wasik, Maria
Komaki, Ritsuko
Gilbert, Mark R.
Mehta, Minesh P.
Aldape, Kenneth D.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[9] RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Gilbert, Mark R.
Dignam, James
Won, Minhee
Blumenthal, Deborah T.
Vogelbaum, Michael A.
Aldape, Kenneth D.
Colman, Howard
Chakravarti, Arnab
Jeraj, Robert
Armstrong, Terri S.
Wefel, Jeffrey Scott
Brown, Paul D.
Jaeckle, Kurt A.
Schiff, David
Atkins, James Norman
Brachman, David
Werner-Wasik, Maria
Komaki, Ritsuko
Sulman, Erik P.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[10] RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Gilbert, Mark R.
Dignam, James
Won, Minhee
Blumenthal, Deborah T.
Vogelbaum, Michael A.
Aldape, Kenneth D.
Colman, Howard
Chakravarti, Arnab
Jeraj, Robert
Armstrong, Terri S.
Wefel, Jeffrey Scott
Brown, Paul D.
Jaeckle, Kurt A.
Schiff, David
Atkins, James Norman
Brachman, David
Werner-Wasik, Maria
Komaki, Ritsuko
Sulman, Erik P.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →